UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 117

Sortiert nach

Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data

Molecules (Basel, Switzerland), 2022-06, Vol.27 (12), p.3680

Fishman, Pnina

2022

Volltextzugriff (PDF)

Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways

Biomolecules (Basel, Switzerland), 2023-10, Vol.13 (11), p.1584

2023

Volltextzugriff (PDF)

Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects

Purinergic signalling, 2023-09, Vol.19 (3), p.513-522

2023

Volltextzugriff (PDF)

Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma

Biomedicines, 2024-04, Vol.12 (4), p.848

2024

Volltextzugriff (PDF)

Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson

Journal of immunology research, 2018, Vol.2018, p.2310970-2310970

2018

Volltextzugriff (PDF)

Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy

Drug design, development and therapy, 2019-01, Vol.13, p.491-497

2019

Volltextzugriff (PDF)

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial

Journal of rheumatology, 2008-01, Vol.35 (1), p.41

2008

Volltextzugriff (PDF)

Pharmacology and therapeutic applications of A3 receptor subtype

Current topics in medicinal chemistry, 2003, Vol.3 (4), p.463

2003

Volltextzugriff (PDF)

Targeting the [A.sub.3] adenosine receptor to treat cytokine release syndrome in cancer immunotherapy

Drug design, development and therapy, 2019-02, Vol.13, p.491

2019

Volltextzugriff (PDF)

A_3 Adenosine Receptor Allosteric Modulator Induces an Anti-Inflammatory Effect: In Vivo Studies and Molecular Mechanism of Action

Mediators of Inflammation, 2014, Vol.2014 (7), p.1-8

2014

Volltextzugriff (PDF)

The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis

Clinical rheumatology, 2016-09, Vol.35 (9), p.2359-2362

2016

Volltextzugriff (PDF)

Targeting the A 3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy

Drug design, development and therapy, 2019, Vol.13, p.491-497

2019

Volltextzugriff (PDF)

Effects of namodenoson on pancreatic carcinoma: Preclinical evidence

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.e15134-e15134

2023

Volltextzugriff (PDF)

An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B

Oncogene, 2004-04, Vol.23 (14), p.2465-2471

2004

Volltextzugriff (PDF)

Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells

Oncogene, 2002-06, Vol.21 (25), p.4060-4064

2002

Volltextzugriff (PDF)

Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models

Journal of rheumatology, 2005-03, Vol.32 (3), p.469

2005

Volltextzugriff (PDF)

MP89-04 CF602 IMPROVES ERECTILE DYSFUNCTION IN DIABETIC RATS

The Journal of urology, 2016-04, Vol.195 (4), p.e1138-e1138

2016

Volltextzugriff (PDF)

Pharmacological and therapeutic effects of A3 adenosine receptor agonists

Drug discovery today, 2012-04, Vol.17 (7-8), p.359-366

2012

Volltextzugriff (PDF)

Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor

Journal of cellular physiology, 2001-01, Vol.186 (1), p.19-23

2001

Volltextzugriff (PDF)

A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model

Andrologia, 2022-10, Vol.54 (9), p.e14498-n/a

2022

Volltextzugriff (PDF)

A3 Adenosine Receptor Allosteric Modulator Induces an Anti-Inflammatory Effect: In Vivo Studies and Molecular Mechanism of Action

Mediators of inflammation, 2014-01, Vol.2014, p.708746

2014

Volltextzugriff (PDF)

The A sub(3) adenosine receptor (A sub(3)AR): therapeutic target and predictive biological marker in rheumatoid arthritis

Clinical rheumatology, 2016-09, Vol.35 (9), p.2359-2362

2016

Volltextzugriff (PDF)

The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice

International journal of molecular medicine, 2019-12, Vol.44 (6), p.2256-2264

2019

Volltextzugriff (PDF)

CF101, An Agonist to the A3 Adenosine Receptor, Enhances the Chemotherapeutic Effect of 5-Fluorouracil in a Colon Carcinoma Murine Model

Neoplasia (New York, N.Y.), 2005-01, Vol.7 (1), p.85-90

2005

Volltextzugriff (PDF)

1 – 25 von 117

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(105)
Mit Volltextzugriff
(95)

Publikationsform

Sprache

Englisch
(117)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(58)
Science & Technology
(58)
Humans
(49)
Animals
(40)
Biological And Medical Sciences
(32)
Mice
(29)
Medical Sciences
(28)
Female
(24)
Male
(23)
Adenosine - Analogs & Derivatives
(20)
Oncology
(20)
Adenosine
(17)
Middle Aged
(16)
A3 Adenosine Receptor
(12)
Adult
(12)
Pharmacology. Drug Treatments
(12)
Adenosine - Pharmacology
(11)
Mice, Inbred C57bl
(11)
Inflammation
(10)
Receptor, Adenosine A3 - Metabolism
(10)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Drugs Targeting the A3 Adenosine Receptor: Human Clinical Study Data

Namodenoson Inhibits the Growth of Pancreatic Carcinoma via Deregulation of the Wnt/β-catenin, NF-κB, and RAS Signaling Pathways

Targeting the A3 adenosine receptor to treat hepatocellular carcinoma: anti-cancer and hepatoprotective effects

Namodenoson at the Crossroad of Metabolic Dysfunction-Associated Steatohepatitis and Hepatocellular Carcinoma

Inhibition of IL-17 and IL-23 in Human Keratinocytes by the A3 Adenosine Receptor Agonist Piclidenoson

Targeting the A3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy

Namodenoson in Advanced Hepatocellular Carcinoma and Child-Pugh B Cirrhosis: Randomized Placebo-Controlled Clinical Trial

Clinical evidence for utilization of the A3 adenosine receptor as a target to treat rheumatoid arthritis: data from a phase II clinical trial

Pharmacology and therapeutic applications of A3 receptor subtype

Targeting the [A.sub.3] adenosine receptor to treat cytokine release syndrome in cancer immunotherapy

A_3 Adenosine Receptor Allosteric Modulator Induces an Anti-Inflammatory Effect: In Vivo Studies and Molecular Mechanism of Action

The A3 adenosine receptor (A3AR): therapeutic target and predictive biological marker in rheumatoid arthritis

Targeting the A 3 adenosine receptor to treat cytokine release syndrome in cancer immunotherapy

Effects of namodenoson on pancreatic carcinoma: Preclinical evidence

An agonist to the A3 adenosine receptor inhibits colon carcinoma growth in mice via modulation of GSK-3 beta and NF-kappa B

Evidence for involvement of Wnt signaling pathway in IB-MECA mediated suppression of melanoma cells

Antiinflammatory effect of A3 adenosine receptor agonists in murine autoimmune arthritis models

MP89-04 CF602 IMPROVES ERECTILE DYSFUNCTION IN DIABETIC RATS

Pharmacological and therapeutic effects of A3 adenosine receptor agonists

Differential effect of adenosine on tumor and normal cell growth: Focus on the A3 adenosine receptor

A3 adenosine receptor allosteric modulator CF602 reverses erectile dysfunction in a diabetic rat model

A3 Adenosine Receptor Allosteric Modulator Induces an Anti-Inflammatory Effect: In Vivo Studies and Molecular Mechanism of Action

The A sub(3) adenosine receptor (A sub(3)AR): therapeutic target and predictive biological marker in rheumatoid arthritis

The A3 adenosine receptor agonist, namodenoson, ameliorates non‑alcoholic steatohepatitis in mice

CF101, An Agonist to the A3 Adenosine Receptor, Enhances the Chemotherapeutic Effect of 5-Fluorouracil in a Colon Carcinoma Murine Model

Suchergebnisse filtern